Thomson A B
Department of Medicine, University of Alberta, Edmonton, Canada.
Hepatogastroenterology. 1992 Feb;39 Suppl 1:14-23.
Gastroesophageal reflux disease (GERD) represents a spectra of symptoms and of reflux damage to the esophagus. This reflux damage is due to a prolonged acid exposure of the esophagus arising from an imbalance between protective motility factors and aggressive acid secretory factors. Initially, patients may be managed by modifying their food intake and by supportive anti-gravity measures. However, many individuals will require drug therapy. Symptomatic relief can be achieved with pro-kinetic agents, antacids, sucralfate suspension, H2-receptor antagonists and H(+)-K+ ATPase pump blockers. There are limitations in the study design of experiments which have compared one agent with another. Accepting these design limitations, it would appear that pump blockers lead to higher rates of endoscopic healing than the use of standard doses of H2-receptor antagonists. However, higher doses of H2-receptor antagonists will likely give higher rates of symptomatic relief and endoscopic healing of GERD. Recurrence of symptoms and esophagitis occur in a high proportion of patients with GERD, and some patients may need to be considered for maintenance therapy.
胃食管反流病(GERD)表现为一系列症状以及食管反流损伤。这种反流损伤是由于食管长期暴露于酸性环境,这是由保护性动力因素和侵袭性胃酸分泌因素之间的失衡所导致的。起初,患者可以通过调整饮食摄入和采取支持性的抗重力措施来进行管理。然而,许多人将需要药物治疗。促动力剂、抗酸剂、硫糖铝混悬液、H2受体拮抗剂和H(+) - K+ ATP酶泵阻滞剂都可以实现症状缓解。比较一种药物与另一种药物的实验研究设计存在局限性。尽管存在这些设计局限性,但似乎泵阻滞剂比使用标准剂量的H2受体拮抗剂能带来更高的内镜愈合率。然而,更高剂量的H2受体拮抗剂可能会使GERD患者获得更高的症状缓解率和内镜愈合率。GERD患者中很大一部分会出现症状复发和食管炎,一些患者可能需要考虑进行维持治疗。